Brain Health

Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.

Video chatting, texting, watching videos, and playing video games were activities most commonly associated with depressive symptoms in adolescents.

According to the authors, being able to identify mood disturbances through passive digital biomarker data can be promising in next-generation predictive, personalized mental health diagnostics.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

Thomas Chen, MD, PhD discussed his innovative approach to brain cancer treatment through NeOnc, Inc.

The authors note this is the first study to assess cerebrovascular endothelial extracellular vesicles within a cognitive condition.

The chief product and strategy officer at Linus Health is hopeful that pharmacists can be key players in the detection of mild cognitive impairment.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

Those with an aneurysm diagnosis who were younger than 40 years of age were observed to have an even higher risk.

The Alzheimer disease treatment landscape is evolving with new FDA-approved antibody therapies and advancements in biomarker testing to enable earlier diagnosis and intervention.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.